.

Important Safety Information

Important Safety Information

IMPORTANT SAFETY INFORMATION

Increased risk of bleeding complications has been observed after administration of similar medicines. Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to monitor for signs of these risks. Seek medical attention if unexpected bleeding occurs.

Increased risk of kidney damage, including potentially fatal acute inflammation of the kidney, has been observed after administration of similar medicines. Your healthcare provider should perform urine testing before you start treatment with SPINRAZA and before each dose to monitor for signs of this risk.

The most common side effects of SPINRAZA include lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome.

These are not all of the possible side effects of SPINRAZA. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking SPINRAZA, tell your healthcare provider if you are pregnant or plan to become pregnant.

Please see full Prescribing Information.

This information is not intended to replace discussions with your healthcare provider.

INDICATION

SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients.

Stay Connected
Sign up with us to receive the latest news, support information, and upcoming events.

Please enter a valid email address.

Why SPINRAZA
How SPINRAZA Works Later-Onset Studies Early-Onset Study Presymptomatic Study Safety Profile
TAKING SPINRAZA
Getting Started Dosing Find a Treatment Center
SPINRAZA STORIES
Adults on SPINRAZA Children on SPINRAZA
WHAT IS SMA
About SMA
Support & Events
Support and Resources Insurance Support SMA360°™ Events FAQs

©2022 Biogen. All rights reserved.
This site is intended for US residents
aged 18 and older.
SPZ-US-3384 v6